BASKET-SMALL 2: advancing DCB beyond in-stent restenosis

Drug-coated balloons (DCB) were first used as a new therapeutic option in the treatment of in-stent restenosis, with proven inhibition of restenosis in clinical studies.1–3 DCB have received a class 1 indication in the 2014 European Society of Cardiology guidelines4 for the treatment of both bare me...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2018-09, Vol.392 (10150), p.802-804
Main Authors: Ho, Hee Hwa, Ong, Paul Jau Lueng
Format: Article
Language:English
Subjects:
Angioplasty
Antiplatelet therapy
Balloon treatment
Cardiology
Cardiovascular disease
Coronary vessels
Dissection
Heart attacks
Implants
Restenosis
Stents
Surgical implants
Thromboembolism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug-coated balloons (DCB) were first used as a new therapeutic option in the treatment of in-stent restenosis, with proven inhibition of restenosis in clinical studies.1–3 DCB have received a class 1 indication in the 2014 European Society of Cardiology guidelines4 for the treatment of both bare metal stent (BMS) and drug-eluting stent (DES) in-stent restenosis. In PCI, DCB is thought to have several advantages over DES because it inhibits excessive neointimal hyperplasia after balloon angioplasty without leaving a permanent metallic frame (thus there is potential for favourable vascular remodelling), eliminates the risk of stent thrombosis, and reduces the duration of dual antiplatelet therapy. [...]there was no routine core-laboratory analysis of the angiographies at baseline and at follow-up.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(18)31926-3